- Home
- QNRX vs RDHL Comparison
QNRX vs RDHL Comparison
Compare QNRX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- RDHL
- Stock Information
- Founded
- QNRX 2018
- RDHL 2009
- Country
- QNRX United States
- RDHL Israel
- Employees
- QNRX 3
- RDHL N/A
- Industry
- QNRX Medical/Dental Instruments
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- RDHL Health Care
- Exchange
- QNRX Nasdaq
- RDHL Nasdaq
- Market Cap
- QNRX 4.0M
- RDHL 3.9M
- IPO Year
- QNRX N/A
- RDHL N/A
- Fundamental
- Price
- QNRX $6.97
- RDHL $1.24
- Analyst Decision
- QNRX
- RDHL
- Analyst Count
- QNRX 0
- RDHL 0
- Target Price
- QNRX N/A
- RDHL N/A
- AVG Volume (30 Days)
- QNRX 4.1K
- RDHL 1.4M
- Earning Date
- QNRX 08-07-2025
- RDHL 08-28-2025
- Dividend Yield
- QNRX N/A
- RDHL N/A
- EPS Growth
- QNRX N/A
- RDHL N/A
- EPS
- QNRX N/A
- RDHL N/A
- Revenue
- QNRX N/A
- RDHL $8,042,999.00
- Revenue This Year
- QNRX N/A
- RDHL $381.91
- Revenue Next Year
- QNRX N/A
- RDHL N/A
- P/E Ratio
- QNRX N/A
- RDHL N/A
- Revenue Growth
- QNRX N/A
- RDHL 23.17
- 52 Week Low
- QNRX $5.01
- RDHL $1.18
- 52 Week High
- QNRX $54.95
- RDHL $15.34
- Technical
- Relative Strength Index (RSI)
- QNRX 26.23
- RDHL 33.26
- Support Level
- QNRX $6.67
- RDHL $1.17
- Resistance Level
- QNRX $8.69
- RDHL $3.31
- Average True Range (ATR)
- QNRX 0.34
- RDHL 0.30
- MACD
- QNRX -0.22
- RDHL -0.09
- Stochastic Oscillator
- QNRX 1.08
- RDHL 2.35
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.